GlobeNewswire: TetraLogic Pharmaceuticals Contains the last 10 of 47 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:12:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/12/29/902176/0/en/TetraLogic-Pharmaceuticals-Corporation-Announces-Completion-of-Sale-of-SMAC-Mimetic-and-HDAC-Inhibitor-Assets-to-Medivir-AB.html?f=22&fvtc=4&fvtv=20663TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB2016-12-29T15:30:00Z<![CDATA[PAOLI, Pa., Dec. 29, 2016 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) (“TetraLogic” or “Company”) and its wholly-owned subsidiary TetraLogic Research and Development Corporation (“TDRC”) today announced that they have completed the sale to Medivir AB (Nasdaq Stockholm:MVIR) (“Medivir”) of their SMAC mimetic program, including their clinical stage asset birinapant, and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir (the “Sale”) for a purchase price of (i) $12 million payable in cash at closing plus (ii) milestone payments of up to $153 million based on the development and commercialization of TetraLogic’s product candidates by Medivir subject to certain conditions and limitations described in the Asset Purchase Agreement for the Sale and (iii) additional earn-out payments based on annual net sales of birinapant, subject to certain conditions and limitations described in the Asset Purchase Agreement for the Sale as follows:]]>https://www.globenewswire.com/news-release/2016/11/02/886000/0/en/TetraLogic-Announces-Agreements-to-Sell-SMAC-mimetic-and-HDAC-inhibitor-assets-to-Medivir-and-to-Restructure-its-Convertible-Senior-Notes-and-Delisting-of-Common-Stock.html?f=22&fvtc=4&fvtv=20663TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock2016-11-02T20:30:00Z<![CDATA[PAOLI, Pa., Nov. 02, 2016 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) (“TetraLogic” or “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that it has entered into an asset purchase agreement with Medivir AB (Nasdaq Stockholm:MVIR) (“Medivir”) to sell its SMAC mimetic program, including its clinical stage asset birinapant, and its topical HDAC inhibitor, SHAPE, to Medivir (the “Sale”). ]]>https://www.globenewswire.com/news-release/2016/01/06/799975/0/en/TetraLogic-Pharmaceuticals-Announces-Data-on-Lead-Clinical-Programs.html?f=22&fvtc=4&fvtv=20663TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs2016-01-06T21:10:54Z<![CDATA[Birinapant Shows No Activity in Randomized Phase 2 MDS Study]]>https://www.globenewswire.com/news-release/2015/11/09/785102/10155534/en/TetraLogic-Pharmaceuticals-Announces-Clinical-Data-on-Birinapant-to-be-Presented-at-the-57th-Annual-American-Society-of-Hematology-Annual-Meeting.html?f=22&fvtc=4&fvtv=20663TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual American Society of Hematology Annual Meeting2015-11-09T12:00:00Z<![CDATA[MALVERN, Pa., Nov. 9, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts discussing clinical data on birinapant will be presented at the 57]]>https://www.globenewswire.com/news-release/2015/11/04/783639/10155069/en/TetraLogic-Reports-Third-Quarter-Financial-Results-and-Provides-Clinical-Programs-Update.html?f=22&fvtc=4&fvtv=20663TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update2015-11-04T21:01:00Z<![CDATA[MALVERN, Pa., Nov. 4, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2015. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.]]>https://www.globenewswire.com/news-release/2015/11/02/782331/10154692/en/TetraLogic-Announces-the-Opening-of-an-IND-for-SHAPE-Gel-in-Alopecia-Areata.html?f=22&fvtc=4&fvtv=20663TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata2015-11-02T12:00:00Z<![CDATA[MALVERN, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase 2 clinical trial of suberohydroxamic acid (4-methoxycarbonyl) phenyl ester (SHAPE) in approximately forty patients with alopecia areata.]]>https://www.globenewswire.com/news-release/2015/08/05/758196/10144888/en/TetraLogic-Reports-Second-Quarter-Financial-Results-and-Provides-Clinical-Programs-Update.html?f=22&fvtc=4&fvtv=20663TetraLogic Reports Second Quarter Financial Results and Provides Clinical Programs Update2015-08-05T20:01:00Z<![CDATA[MALVERN, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the second quarter ended June 30, 2015. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.]]>https://www.globenewswire.com/news-release/2015/07/29/755927/10143636/en/TetraLogic-to-Present-at-the-Jefferies-2015-Hepatitis-B-Summit.html?f=22&fvtc=4&fvtv=20663TetraLogic to Present at the Jefferies 2015 Hepatitis B Summit2015-07-29T11:31:50Z<![CDATA[MALVERN, Pa., July 29, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) today announced that the Company will present at the Jefferies 2015 Hepatitis B Summit on Thursday, August 6, 2015 at 1:45 p.m. Eastern Time at the Boston Harbor Hotel. J. Kevin Buchi, CEO, will provide an overview of the Company, the Hepatitis B program and its corporate activities.]]>https://www.globenewswire.com/news-release/2015/07/20/753549/10142328/en/TetraLogic-Provides-Update-on-Hepatitis-B-Clinical-Program.html?f=22&fvtc=4&fvtv=20663TetraLogic Provides Update on Hepatitis B Clinical Program2015-07-20T20:02:00Z<![CDATA[MALVERN, Pa., July 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) a clinical-stage biopharmaceutical company focuses on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today provided an update on the status of its hepatitis B virus (HBV) clinical program.]]>https://www.globenewswire.com/news-release/2015/06/30/748742/10140249/en/TetraLogic-Announces-Update-on-MDS-Clinical-Program.html?f=22&fvtc=4&fvtv=20663TetraLogic Announces Update on MDS Clinical Program2015-06-30T20:01:00Z<![CDATA[MALVERN, Pa., June 30, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced preliminary data from the ongoing Phase 2A study of birinapant in combination with azacitidine in first line higher risk myelodysplastic syndromes (MDS). The study is being conducted as a precursor to the ongoing randomized Phase 2B study.]]>